Perrigo Company plc (0Y5E.L)
USD 26.0
(-2.11%)
USD 26.0
(-2.11%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -12.7 Million USD | 90.3% |
| 2022 | -130.9 Million USD | 0.0% |
| 2021 | -130.9 Million USD | 19.5% |
| 2020 | -162.6 Million USD | -211.29% |
| 2019 | 146.1 Million USD | 11.53% |
| 2018 | 131 Million USD | 9.53% |
| 2017 | 119.6 Million USD | 102.98% |
| 2016 | -4.01 Billion USD | -3237.45% |
| 2015 | 127.9 Million USD | -37.7% |
| 2014 | 205.3 Million USD | -53.54% |
| 2013 | 441.9 Million USD | 10.03% |
| 2012 | 401.61 Million USD | 18.4% |
| 2011 | 339.19 Million USD | 52.42% |
| 2010 | 222.54 Million USD | 54.49% |
| 2009 | 144.04 Million USD | 6.1% |
| 2008 | 135.77 Million USD | 83.98% |
| 2007 | 73.79 Million USD | 3.36% |
| 2006 | 71.4 Million USD | 120.23% |
| 2005 | -352.98 Million USD | -538.12% |
| 2004 | 80.56 Million USD | 49.07% |
| 2003 | 54.04 Million USD | 7.67% |
| 2002 | 50.19 Million USD | 81.5% |
| 2001 | 27.65 Million USD | 43.31% |
| 2000 | 19.29 Million USD | 1186.53% |
| 1999 | 1.5 Million USD | 102.91% |
| 1998 | -51.6 Million USD | -214.67% |
| 1997 | 45 Million USD | 13.07% |
| 1996 | 39.8 Million USD | -10.36% |
| 1995 | 44.4 Million USD | -18.98% |
| 1994 | 54.8 Million USD | 22.87% |
| 1993 | 44.6 Million USD | 55.94% |
| 1992 | 28.6 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 4.09 Million USD | 112.69% |
| 2024 Q2 | -105.7 Million USD | -2678.05% |
| 2023 Q4 | -32.3 Million USD | -327.46% |
| 2023 Q2 | 8.4 Million USD | 863.64% |
| 2023 Q1 | -1.1 Million USD | 91.34% |
| 2023 FY | -12.7 Million USD | 90.3% |
| 2023 Q3 | 14.2 Million USD | 69.05% |
| 2022 Q1 | -1.3 Million USD | -113.54% |
| 2022 FY | -130.9 Million USD | 0.0% |
| 2022 Q3 | -52.1 Million USD | 19.72% |
| 2022 Q4 | -12.7 Million USD | 75.62% |
| 2022 Q2 | -64.9 Million USD | -4892.31% |
| 2021 Q3 | -58.9 Million USD | -2.08% |
| 2021 FY | -130.9 Million USD | 19.5% |
| 2021 Q1 | 38.1 Million USD | 121.77% |
| 2021 Q2 | -57.7 Million USD | -251.44% |
| 2021 Q4 | 9.6 Million USD | 116.3% |
| 2020 Q1 | 106.4 Million USD | 660.0% |
| 2020 Q4 | -175 Million USD | -13.2% |
| 2020 Q3 | -154.6 Million USD | -355.12% |
| 2020 FY | -162.6 Million USD | -211.29% |
| 2020 Q2 | 60.6 Million USD | -43.05% |
| 2019 FY | 146.1 Million USD | 11.53% |
| 2019 Q3 | 92.2 Million USD | 924.44% |
| 2019 Q4 | -19 Million USD | -120.61% |
| 2019 Q1 | 63.9 Million USD | -21.5% |
| 2019 Q2 | 9 Million USD | -85.92% |
| 2018 Q4 | 81.4 Million USD | 220.59% |
| 2018 FY | 131 Million USD | 9.53% |
| 2018 Q2 | 36.2 Million USD | -55.2% |
| 2018 Q1 | 80.8 Million USD | 10.38% |
| 2018 Q3 | -67.5 Million USD | -286.46% |
| 2017 Q1 | 71.6 Million USD | 102.74% |
| 2017 Q2 | -69.6 Million USD | -197.21% |
| 2017 Q3 | 44.5 Million USD | 163.94% |
| 2017 Q4 | 73.2 Million USD | 64.49% |
| 2017 FY | 119.6 Million USD | 102.98% |
| 2016 Q4 | -2.61 Billion USD | -108.52% |
| 2016 FY | -4.01 Billion USD | -3237.45% |
| 2016 Q2 | 194.3 Million USD | 245.98% |
| 2016 Q1 | -133.1 Million USD | -24.39% |
| 2016 Q3 | -1.25 Billion USD | -746.01% |
| 2015 Q1 | -94.9 Million USD | -235.19% |
| 2015 Q4 | -107 Million USD | -195.03% |
| 2015 FY | 127.9 Million USD | -37.7% |
| 2015 Q2 | 56.4 Million USD | 159.43% |
| 2015 Q3 | 112.6 Million USD | 99.65% |
| 2014 Q3 | 96.3 Million USD | -26.99% |
| 2014 FY | 205.3 Million USD | -53.54% |
| 2014 Q1 | 48.1 Million USD | 155.93% |
| 2014 Q2 | 131.9 Million USD | 174.22% |
| 2014 Q4 | 70.2 Million USD | -27.1% |
| 2013 Q3 | 111.4 Million USD | -5.94% |
| 2013 Q4 | -86 Million USD | -177.2% |
| 2013 Q1 | 111.92 Million USD | 5.63% |
| 2013 FY | 441.9 Million USD | 10.03% |
| 2013 Q2 | 118.44 Million USD | 5.82% |
| 2012 FY | 401.61 Million USD | 18.4% |
| 2012 Q3 | 105.58 Million USD | -8.74% |
| 2012 Q2 | 115.68 Million USD | -0.03% |
| 2012 Q1 | 115.72 Million USD | 16.03% |
| 2012 Q4 | 105.95 Million USD | 0.36% |
| 2011 Q1 | 89.08 Million USD | -1.2% |
| 2011 FY | 339.19 Million USD | 52.42% |
| 2011 Q4 | 99.73 Million USD | 41.56% |
| 2011 Q3 | 70.45 Million USD | -17.66% |
| 2011 Q2 | 85.57 Million USD | -3.95% |
| 2010 Q3 | 74.37 Million USD | 50.41% |
| 2010 Q4 | 90.16 Million USD | 21.23% |
| 2010 Q1 | 60.9 Million USD | 19.67% |
| 2010 Q2 | 49.44 Million USD | -18.81% |
| 2010 FY | 222.54 Million USD | 54.49% |
| 2009 Q1 | 45.89 Million USD | 83.64% |
| 2009 Q3 | 61.29 Million USD | 74.14% |
| 2009 Q4 | 50.89 Million USD | -16.97% |
| 2009 FY | 144.04 Million USD | 6.1% |
| 2009 Q2 | 35.2 Million USD | -23.3% |
| 2008 Q4 | 24.99 Million USD | -34.16% |
| 2008 Q1 | 39.96 Million USD | 16.56% |
| 2008 Q2 | 27.49 Million USD | -31.2% |
| 2008 Q3 | 37.95 Million USD | 38.04% |
| 2008 FY | 135.77 Million USD | 83.98% |
| 2007 Q4 | 34.28 Million USD | 0.79% |
| 2007 FY | 73.79 Million USD | 3.36% |
| 2007 Q1 | 17.05 Million USD | -19.12% |
| 2007 Q3 | 34.01 Million USD | 81.23% |
| 2007 Q2 | 18.77 Million USD | 10.06% |
| 2006 FY | 71.4 Million USD | 120.23% |
| 2006 Q4 | 21.08 Million USD | 24.91% |
| 2006 Q3 | 16.88 Million USD | 37.68% |
| 2006 Q2 | 12.26 Million USD | -41.22% |
| 2006 Q1 | 20.86 Million USD | -17.76% |
| 2005 Q2 | -6.96 Million USD | 98.16% |
| 2005 FY | -352.98 Million USD | -538.12% |
| 2005 Q4 | 25.36 Million USD | 96.47% |
| 2005 Q3 | 12.91 Million USD | 285.42% |
| 2005 Q1 | -379.43 Million USD | -2495.73% |
| 2004 Q2 | 8.08 Million USD | -54.42% |
| 2004 Q1 | 17.73 Million USD | -53.61% |
| 2004 FY | 80.56 Million USD | 49.07% |
| 2004 Q4 | 15.83 Million USD | -9.9% |
| 2004 Q3 | 17.57 Million USD | 117.41% |
| 2003 Q1 | 14.13 Million USD | -15.95% |
| 2003 Q4 | 38.23 Million USD | 131.61% |
| 2003 Q2 | 4.32 Million USD | -69.4% |
| 2003 Q3 | 16.5 Million USD | 281.78% |
| 2003 FY | 54.04 Million USD | 7.67% |
| 2002 Q3 | 20.01 Million USD | 1462.14% |
| 2002 Q1 | 19.26 Million USD | 16.28% |
| 2002 FY | 50.19 Million USD | 81.5% |
| 2002 Q4 | 16.81 Million USD | -15.98% |
| 2002 Q2 | 1.28 Million USD | -93.35% |
| 2001 Q4 | 16.56 Million USD | 26.55% |
| 2001 Q1 | 10.1 Million USD | 1131.83% |
| 2001 FY | 27.65 Million USD | 43.31% |
| 2001 Q2 | 6.2 Million USD | -38.61% |
| 2001 Q3 | 13.09 Million USD | 111.09% |
| 2000 Q1 | 6.37 Million USD | -42.05% |
| 2000 FY | 19.29 Million USD | 1186.53% |
| 2000 Q3 | 10.53 Million USD | 230.6% |
| 2000 Q2 | -8.06 Million USD | -226.53% |
| 2000 Q4 | 820 Thousand USD | -92.22% |
| 1999 Q3 | 10 Million USD | 433.33% |
| 1999 FY | 1.5 Million USD | 102.91% |
| 1999 Q1 | 9.7 Million USD | 36.62% |
| 1999 Q2 | -3 Million USD | -130.93% |
| 1999 Q4 | 11 Million USD | 10.0% |
| 1998 Q4 | 7.1 Million USD | 157.26% |
| 1998 FY | -51.6 Million USD | -214.67% |
| 1998 Q2 | -88.7 Million USD | -1033.68% |
| 1998 Q1 | 9.5 Million USD | -34.03% |
| 1998 Q3 | -12.4 Million USD | 86.02% |
| 1997 FY | 45 Million USD | 13.07% |
| 1997 Q3 | 13.2 Million USD | 46.67% |
| 1997 Q2 | 9 Million USD | -22.41% |
| 1997 Q1 | 11.6 Million USD | -15.33% |
| 1997 Q4 | 14.4 Million USD | 9.09% |
| 1996 Q3 | 10.7 Million USD | 122.92% |
| 1996 Q2 | 4.8 Million USD | -54.72% |
| 1996 Q1 | 10.6 Million USD | -13.11% |
| 1996 FY | 39.8 Million USD | -10.36% |
| 1996 Q4 | 13.7 Million USD | 28.04% |
| 1995 FY | 44.4 Million USD | -18.98% |
| 1995 Q3 | 12.2 Million USD | 125.93% |
| 1995 Q2 | 5.4 Million USD | -52.63% |
| 1995 Q4 | 12.2 Million USD | 0.0% |
| 1995 Q1 | 11.4 Million USD | -11.63% |
| 1994 Q4 | 12.9 Million USD | -12.84% |
| 1994 FY | 54.8 Million USD | 22.87% |
| 1994 Q3 | 14.8 Million USD | 27.59% |
| 1994 Q1 | 13.3 Million USD | -13.07% |
| 1994 Q2 | 11.6 Million USD | -12.78% |
| 1993 FY | 44.6 Million USD | 55.94% |
| 1993 Q1 | 11.3 Million USD | -4.24% |
| 1993 Q2 | 11.2 Million USD | -0.88% |
| 1993 Q3 | 14.6 Million USD | 30.36% |
| 1993 Q4 | 15.3 Million USD | 4.79% |
| 1992 Q4 | 11.8 Million USD | 13.46% |
| 1992 Q1 | 8.2 Million USD | 22.39% |
| 1992 Q2 | 7.6 Million USD | -7.32% |
| 1992 Q3 | 10.4 Million USD | 36.84% |
| 1992 FY | 28.6 Million USD | 0.0% |
| 1991 Q4 | 6.7 Million USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 91.711% |
| Dynavax Technologies Corporation | -6.38 Million USD | -98.779% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1065.046% |
| Illumina, Inc. | -1.16 Billion USD | 98.906% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.212% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 97.14% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.853% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 100.935% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 88.513% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.321% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 68.138% |
| Waters Corporation | 642.23 Million USD | 101.977% |
| Biogen Inc. | 1.16 Billion USD | 101.094% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 95.074% |
| Evolus, Inc. | -61.68 Million USD | 79.412% |
| Adicet Bio, Inc. | -142.65 Million USD | 91.098% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 89.284% |
| bluebird bio, Inc. | -211.91 Million USD | 94.007% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 93.931% |
| FibroGen, Inc. | -284.23 Million USD | 95.532% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 101.024% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 71.527% |
| Homology Medicines, Inc. | -53.74 Million USD | 76.369% |
| Geron Corporation | -184.12 Million USD | 93.103% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 97.115% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 91.622% |
| Myriad Genetics, Inc. | -112 Million USD | 88.661% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 85.215% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 97.361% |
| Zoetis Inc. | 2.34 Billion USD | 100.542% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 76.563% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 101.61% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 107.576% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.351% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 69.905% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 96.533% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 95.401% |
| Verastem, Inc. | -87.36 Million USD | 85.464% |
| Nektar Therapeutics | -276.05 Million USD | 95.399% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 94.691% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 85.647% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 97.63% |
| OPKO Health, Inc. | -188.86 Million USD | 93.276% |
| Exelixis, Inc. | 207.76 Million USD | 106.113% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 105.086% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 111.965% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 73.266% |
| uniQure N.V. | -308.47 Million USD | 95.883% |
| Imunon, Inc. | -19.51 Million USD | 34.922% |
| Blueprint Medicines Corporation | -506.98 Million USD | 97.495% |
| Insmed Incorporated | -749.56 Million USD | 98.306% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 104.51% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 96.393% |
| TG Therapeutics, Inc. | 12.67 Million USD | 200.221% |
| Incyte Corporation | 597.59 Million USD | 102.125% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 98.33% |